Grail CFO Aaron Freidin sells $382,679 in company stock

GRAIL's CFO, Aaron Freidin, divested a total of 4,100 shares, generating $382,679 in proceeds, according to wire reports dated September 21, 2026. The transactions were executed within a narrow $92.26 to $95.00 price range. Freidin initiated 1,779 shares at an average cost of $92.26, spanning prices between $92.19 and $93.00. An additional 1,800 shares were sold at a weighted average price of $93.92, with prices fluctuating between $93.89 and $94.33.

Finally, 521 shares were disposed at $95.00 per share. All sales adhered to a pre-approved Rule 10b5-1 trading plan, adopted on December 11, 2025. Post-transaction, Freidin's ownership of GRAIL stock stands at 248,983 shares. The insider sale occurred at a time when GRAIL's stock was trading close to its 52-week high of $127.67, up 154% over the past year and 162% in the last six months.

Despite this surge, InvestingPro analysis suggests GRAIL is overvalued, placing the stock on the platform's Most Overvalued list. Investors should be aware of GRAIL's high volatility, as indicated by a beta of 3.25. The company reported strong Q2 revenue of $44.7 million, exceeding estimates, but also posted a loss of $2.56 per share, indicating ongoing financial challenges.

An FDA advisory committee's endorsement of GRAIL's Galleri test, designed for multi-cancer detection, bodes well for the product's approval process. Regulatory analysts from Mizuho and Canaccord Genuity raised price targets to $100 and reiterated Buy ratings, respectively. However, RBC Capital's coverage initiated a Sector Perform rating with an $84 target, citing concerns about reimbursement and adoption.

These developments underscore GRAIL's ongoing efforts to tackle regulatory hurdles and capitalize on growth opportunities in cancer detection.